Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 4, 1998, Pages 352-354

  Rosenthal, Mark A ^a,b   Oratz, Ruth ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

13 cis retinoic acid; Alpha 2b interferon; Melanoma

Indexed keywords

CHOLESTEROL; ISOTRETINOIN; RECOMBINANT ALPHA2B INTERFERON; TRIACYLGLYCEROL;

ADULT; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MELANOMA; METASTASIS; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON ALFA-2B; ISOTRETINOIN; KERATOLYTIC AGENTS; MALE; MELANOMA; MIDDLE AGED;

EID: 0031819261     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199808000-00007     Document Type: Article

References (10)

1. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 4th ed. Philadelphia: JB Lippincott, 1993:1612-61.
2. Kirkwood JM. Biologic therapy with interferon α and β: clinical applications-melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. principles and practice. Philadelphia: JB Lippincott, 1995:388-411.
3. Smith MA, Parkinson DR, Cheson BD, et al. Retinoids in cancer Therapy. J Clin Oncol 1992;10:839-64.
4. Meyskens F, Fuller B. Characterization of the effects of different retinoids on the growth and differentiation of human melanoma cell lines and selected subclones. Cancer Res 1980;40:2194-6.
5. Ho CK. Synergistic anticellular effect of a combination of beta-interferon and retinoic acid against U937 cells. Cancer Res 1985;45:5348-51.
6. Hemmi H, Breitman TR. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987;69:501-7.
7. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13 cis retinoid acid plus interferon alpha 2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992:241-5.
8. Triozzi PL, Walker MJ, Pellegrini AE, Dayton MA. Isoretinoin and recombinant interferon alpha 2a therapy of metastatic melanoma. Cancer Invest 1996;14:293-8.
9. Fierlbeck G, Schreiner T, Rassner G. Treatment of advanced malignant melanoma with highly purified natural interferon α and isoretinoin [Abstract]. Twelfth Asia Pacific Cancer Conference. Singapore, 1994:366.
10. Dhinga K, Papadopoulos N, Lippman S, Lotan R, Legha SS. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest New Drugs3 1993;11:39-43.